Heaton KM - Search Results

1

Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma.

Heaton KM, Sussman JJ, Gershenwald JE, Lee JE, Reintgen DS, Mansfield PF, Ross MI. Heaton KM, et al. Ann Surg Oncol. 1998 Jun;5(4):322-8. doi: 10.1007/BF02303495. Ann Surg Oncol. 1998. PMID: 9641453

2

Surgical management and prognostic factors in patients with subungual melanoma.

Heaton KM, el-Naggar A, Ensign LG, Ross MI, Balch CM. Heaton KM, et al. Ann Surg. 1994 Feb;219(2):197-204. doi: 10.1097/00000658-199402000-00012. Ann Surg. 1994. PMID: 8129491 Free PMC article.

3

Prognostic implications of DNA index in patients with stage III cutaneous melanoma.

Heaton KM, Rippon MB, el-Naggar A, Tucker SL, Ross MI, Balch CM. Heaton KM, et al. Am J Surg. 1993 Dec;166(6):648-52; discussion 652-3. doi: 10.1016/s0002-9610(05)80672-5. Am J Surg. 1993. PMID: 8273843

4

Feasibility of breast conservation therapy in metachronous or synchronous bilateral breast cancer.

Heaton KM, Peoples GE, Singletary SE, Feig BW, Ross MI, Ames FC, Buchholz TA, Strom EA, McNeese MD, Hunt KK. Heaton KM, et al. Ann Surg Oncol. 1999 Jan-Feb;6(1):102-8. doi: 10.1007/s10434-999-0102-8. Ann Surg Oncol. 1999. PMID: 10030422

5

Local-regional control in breast cancer patients with a possible genetic predisposition.

Freedman LM, Buchholz TA, Thames HD, Strom EA, McNeese MD, Hortobagyi GN, Singletary SE, Heaton KM, Hunt KK. Freedman LM, et al. Among authors: heaton km. Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):951-7. doi: 10.1016/s0360-3016(00)00761-6. Int J Radiat Oncol Biol Phys. 2000. PMID: 11072150

6

Induction of lymphokine-activated killing with reduced secretion of interleukin-1 beta, tumor necrosis factor-alpha, and interferon-gamma by interleukin-2 analogs.

Heaton KM, Ju G, Grimm EA. Heaton KM, et al. Ann Surg Oncol. 1994 May;1(3):198-203. doi: 10.1007/BF02303524. Ann Surg Oncol. 1994. PMID: 7842289

7

Differential inhibition of lymphokine-activated killing, proliferation, and cytokine secretion by humanized antibodies against the low- and intermediate-affinity interleukin-2 receptors. A novel model for activation of human peripheral blood mononuclear cells by interleukin 2.

Heaton KM, Grimm EA. Heaton KM, et al. Hum Immunol. 1995 Mar;42(3):274-80. doi: 10.1016/0198-8859(94)00106-z. Hum Immunol. 1995. PMID: 7759316

8

Characterization of lymphokine-activated killing by human peripheral blood mononuclear cells stimulated with interleukin 2 (IL-2) analogs specific for the intermediate affinity IL-2 receptor.

Heaton KM, Ju G, Morris DK, Delisio K, Bailon P, Grimm EA. Heaton KM, et al. Cell Immunol. 1993 Mar;147(1):167-79. doi: 10.1006/cimm.1993.1057. Cell Immunol. 1993. PMID: 8462109

9

Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy.

Heaton KM, Ju G, Grimm EA. Heaton KM, et al. Cancer Res. 1993 Jun 1;53(11):2597-602. Cancer Res. 1993. PMID: 8495422

10

Cytokine combinations in immunotherapy for solid tumors: a review.

Heaton KM, Grimm EA. Heaton KM, et al. Cancer Immunol Immunother. 1993 Sep;37(4):213-9. doi: 10.1007/BF01518513. Cancer Immunol Immunother. 1993. PMID: 8348559 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16 results

Search Page

Filters